UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

March 31, 2021

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________________ to _____________________

Commission File Number : 333-188152

333-188152

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Nevada		33-1229553
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
(State or other jurisdiction ofincorporation or organization)		(IRS EmployerIdentification No.)
Gewerbestrasse 10, Cham, Switzerland		6330
(Address of principal executive offices)		(Zip Code)

(646)224-1160

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

207,~~603~~753,598 common shares issued and outstanding as of ~~May~~November 1404, 2021.

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition or Plan of Operation	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18
PART II - OTHER INFORMATION		19
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	20
SIGNATURES		21

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Bionovate Technologies Corp

BALANCE SHEETS

(Unaudited)

	March 31,			June 30,
	September 30,			June 30,
	2021			~~2020~~2021
ASSETS
Current Assets
Cash	$	—-		$	—-
Total Current Assets		—-			—-
TOTAL ASSETS	$	—-		$	—-
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	~~252~~287,~~554~~317		$	~~211~~265,~~290~~825
Due to related party		4552,~~709~~153			—52,009
Convertible notes payable		185,375			185,375
Total Current Liabilities		~~483~~524,~~638~~845			~~396~~503,~~665~~209
TOTAL LIABILITIES		~~483~~524,~~638~~845			~~396~~503,~~665~~209
Stockholders' Deficit
Preferred stock: 90,000,000 authorized; $0.0001 par value - no shares issued and outstanding		—-			—-
Common stock: 100,000,000 authorized; $0.0001 par value
Common stock: 100,000,000 authorized; $0.0001 par value 7,753,598 shares issued and outstanding		775			775
45,603,598 and 59,423,598 shares issued and outstanding		4,560			5,942
Additional paid in capital		2,300,800			2,300,800
Additional paid in capital		2,297,015			2,295,633
Accumulated deficit		(2,826,420	)		(2,804,784	)
Accumulated deficit		(2,785,213	)		(2,698,240	)
Total Deficit		(524,845	)		(503,209	)
Total Deficit		(483,638	)		(396,665	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	-		$	-
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	—		$	—

The accompanying notes are an integral part of these unaudited financial statements

3 Table of Contents

~~Table~~Bionovate ofTechnologies ~~Contents~~Corp

~~Bionovate~~STATEMENT ~~Technologies~~OF ~~Corp~~OPERATIONS

~~STATEMENT OF OPERATIONS~~(Unaudited)

(Unaudited)

	Three Months Ended
	September 30,
	2021			2020

Revenues	$	-		$	-

Operating Expenses
Professional fees		6,279			3,622
Total operating expenses		6,279			3,622

Net loss from operations		(6,279	)		(3,622	)

Other income (expense)
Interest expense		(15,357	)		(19,252	)
Total other expense		(15,357	)		(19,252	)

Net loss before taxes		(21,636	)		(22,874	)

Net loss	$	(21,636	)	$	(22,874	)

Basic and dilutive loss per share
Net loss per share	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding		7,753,598			59,423,598

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2021			2020			2021			2020
Revenues	$	—		$	—		$	—		$	—
Operating Expenses
General and administration		—			—			850			—
Professional fees		16,685			2,748			40,145			27,110
Total operating expenses		16,685			2,748			40,995			27,110
Net loss from operations		(16,685	)		(2,748	)		(40,995	)		(27,110	)
Other income (expense)
Realized foreign currency gain (loss)		46			210			(236	)		103
Interest expense		(15,026	)		(21,600	)		(45,742	)		(72,076	)
Total other expense		(14,980	)		(21,390	)		(45,978	)		(71,973	)
Net loss before taxes		(31,665	)		(24,138	)		(86,973	)		(99,083	)
Net loss	$	(31,665	)	$	(24,138	)	$	(86,973	)	$	(99,083	)
Basic and dilutive loss per share
Net loss	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Weighted average number of shares outstanding		45,603,598			40,520,545			54,026,737			13,512,860

The accompanying notes are an integral part of these unaudited financial statements

~~The~~4 ~~accompanying~~Table ~~notes are an integral part~~ of ~~these unaudited financial statements~~Contents

4Bionovate Technologies Corp

~~Table~~STATEMENT ofOF ~~Contents~~STOCKHOLDERS’ DEFICIENCY

~~Bionovate Technologies Corp~~(Unaudited)

~~STATEMENT~~For OFthe ~~STOCKHOLDERS’~~Three ~~DEFICIENCY~~Months Ended September 30, 2021

(Unaudited)

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total

Balance, June 30, 2021		7,753,598	$	775	$	2,300,800	$	(2,804,784	)	$	(503,209	)

Net loss		-		-		-		(21,636	)		(21,636	)

Balance, September 30, 2021		7,753,598	$	775	$	2,300,800	$	(2,826,420	)	$	(524,845	)

For the Three ~~and Nine~~ Months Ended ~~March~~September 3130, ~~2021~~2020

							Additional
	Common Stock						Paid in		Accumulated
	Shares			Amount			Capital		Deficit			Total
Balance, June 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,698,240	)	$	(396,665	)
Net loss		—-			—-			—-		(22,874	)		(22,874	)
Balance, September 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,721,114	)	$	(419,539	)
Cancellation of shares		(13,820,000	)		(1,382	)		1,382		—			—
Net loss		—			—			—		(32,434	)		(32,434	)
Balance, December 31, 2020		45,603,598		$	4,560		$	2,297,015	$	(2,753,548	)	$	(451,973	)
Net loss		—			—			—		(31,665	)		(31,665	)
Balance, March 31, 2021		45,603,598		$	4,560		$	2,297,015	$	(2,785,213	)	$	(483,638	)

5The accompanying notes are an integral part of these unaudited financial statements

5 Table of Contents

~~For~~Bionovate ~~the~~Technologies ~~Nine Months Ended March 31, 2020~~Corp

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, June 30, 2019		155,798	$	15	$	2,243,891	$	(2,576,195	)	$	(332,289	)
Beneficial conversion feature		—		—		526		—			526
Net loss		—		—		—		(29,376	)		(29,376	)
Balance, September 30, 2019		155,798	$	15	$	2,244,417	$	(2,605,571	)	$	(361,139	)
Beneficial conversion feature		—		—		18,892		—			18,892
Net loss		—		—		—		(45,569	)		(45,569	)
Balance, December 31, 2019		155,798	$	15	$	2,263,309	$	(2,651,140	)	$	(387,816	)
Common shares issued for conversion of debt		59,267,800		5,927		24,490		—			30,417
Beneficial conversion feature		—		—		5,834		—			5,834
Net loss		—		—		—		(24,138	)		(24,138	)
Balance, March 31, 2020		59,423,598	$	5,942	$	2,293,633	$	(2,675,278	)	$	(375,703	)

STATEMENT OF CASH FLOWS

~~The accompanying notes are an integral part of these unaudited financial statements~~(Unaudited)

	Three Months Ended
	September 30,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(21,636	)	$	(22,874	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Expenses paid by related party		144			3,840
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		21,492			19,034
Net cash provided by operating activities		-			-

Net change in cash and cash equivalents		-			-
Cash, beginning of period		-			-
Cash, end of period	$	-		$	-

Supplemental cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

~~Table~~The accompanying notes are an integral part of ~~Contents~~these unaudited financial statements

~~Bionovate~~6 ~~Technologies~~Table ~~Corp~~of Contents

~~STATEMENT~~Bionovate OFTechnologies ~~CASH FLOWS~~Corp

~~(Unaudited)~~NOTES TO THE FINANCIAL STATEMENTS

	Nine Months Ended
	March 31,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(86,973	)	$	(99,083	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Expenses paid by convertible notes		—			25,252
Expenses paid by related party		45,709			—
Amortization of debt discount		—			25,252
Foreign currency adjustment		236			(103	)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		41,028			48,682
Net cash provided by operating activities		—			—
Net change in cash and cash equivalents		—			—
Cash, beginning of period		—			—
Cash, end of period	$	—		$	—
Supplemental cash flow information
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—
Non-cash transactions:
Beneficial conversion feature	$	—		$	25,252
Cancellation of shares	$	1,382		$	—
Common stock issued for conversion of debt	$	—		$	30,417

September 30, 2021

~~The~~NOTE ~~accompanying~~1 ~~notes~~– ~~are~~NATURE anAND ~~integral~~CONTINUANCE ~~part~~OF ~~of these unaudited financial statements~~OPERATIONS

7Bionovate Technologies Corp. (the “Company”, or the “Corporation”) was incorporated in the state of Nevada, United States on October 24, 2012 under the name MJP International Ltd. On December 1, 2017, the Company’s corporate name was changed to Bionovate Technologies Corp.

~~Table~~On ofOctober ~~Contents~~7, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).

~~Bionovate~~Pursuant ~~Technologies~~to ~~Corp~~the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit, 54,270,000 shares (the “Exchange Shares”), the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.

~~NOTES~~The TOShare ~~THE~~Exchange ~~FINANCIAL~~Agreement ~~STATEMENTS~~contains customary representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement

~~March~~The ~~31,~~share ~~2021~~exchange agreement gave the other party 90 days to transfer shares of Digital to Bionovate. Bionovate did not receive these shares yet and does not own any of Digital Diagnostics as of the date of this report.

~~NOTE~~GOING ~~1 – NATURE AND CONTINUANCE OF OPERATIONS~~CONCERN

~~Bionovate~~The ~~Technologies~~accompanying ~~Corp.~~financial ~~(the~~statements ~~“Company”,~~have orbeen ~~the~~prepared ~~“Corporation”)~~in ~~was~~conformity ~~incorporated~~with accounting principles generally accepted in the ~~state~~United States of ~~Nevada~~America, ~~United~~which ~~States~~contemplate oncontinuation ~~October~~of ~~24,~~the ~~2012~~Company ~~under~~as a going concern. However, the ~~name~~Company ~~MJP~~has ~~International~~an ~~Ltd.~~accumulated Ondeficit ~~December~~at 1September 30, ~~2017~~2021 of $2,826,420, ~~the~~is ~~Company’s~~in ~~corporate~~a ~~name~~net ~~was~~liability ~~changed~~position and needs cash to ~~Bionovate~~maintain ~~Technologies~~its ~~Corp~~operations.

~~The~~These ~~Corporation~~factors ~~was~~raise ~~formed~~substantial ~~and~~doubt ~~organized~~about the Company’s ability to ~~capitalize~~continue onas ~~new~~a ~~opportunities~~going ~~found~~concern. inThe ~~the~~accompanying ~~North~~financial ~~American~~statements ~~market~~do ~~for~~not ~~light-emitting~~include ~~diode~~any ~~(“LED”)~~adjustments ~~lighting.~~that ~~With~~might ~~China~~result asfrom the ~~manufacturing~~outcome ~~backbone~~ of ~~future~~this ~~LED~~uncertainty. ~~products,~~The ~~the~~Company’s ~~Corporation~~continued ~~has~~existence ~~set~~is updependent anupon ~~office~~management’s inability ~~Guangzhou,~~to ~~China~~develop inprofitable ~~search~~operations, ofcontinued ~~high-quality~~contributions ~~products~~from ~~offered~~the byCompany’s ~~reputable~~executive ~~manufacturers~~officers to befinance ~~introduced~~its tooperations ~~Canada,~~and the ~~United~~ability ~~States,~~to ~~and~~obtain ~~abroad.~~additional ~~The~~funding ~~Corporation~~sources ~~has~~to ~~set~~explore ~~out~~potential ~~further~~strategic ~~details~~relationships ofand ~~the~~to ~~acquisition~~provide ~~below~~capital asand ~~well~~other asresources infor ~~Notes~~the 3further development and 4marketing toof ~~these~~the ~~consolidated~~Company’s ~~financial~~products ~~statements~~and business.

~~Bionovate~~NOTE ~~Technologies~~2– ~~Corp.~~SUMMARY ~~focuses~~OF onSIGNIFICANT ~~investments~~ACCOUNTING and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device.POLICIES

OnBasis ~~October~~of 7, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).Presentation

~~Pursuant~~The toaccompanying ~~the~~unaudited ~~Share~~financial ~~Exchange~~statements ~~Agreement,~~have been prepared in ~~exchange~~accordance with generally accepted accounting principles for interim financial information and with the ~~acquisition~~instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the ~~outstanding~~information ~~Company~~and ~~shares~~footnotes ~~which~~required ~~Evergreen~~by ~~owns,~~generally toaccepted ~~wit, 54,270,000 shares~~accounting (principles for complete financial statements. In the ~~“Exchange~~opinion ~~Shares”)~~of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the ~~Company~~three ~~will~~months ~~receive 12~~ended September 30,~~500 shares~~ 2021, are not necessarily indicative of ~~Digital~~the ~~Diagnostics~~results AGthat ~~(“Digital”)~~may ~~owned~~be byexpected ~~Human~~for ~~Data~~the fiscal year ending June 30, ~~which~~2022. ~~equates~~For further information, refer to ~~25%~~ ofthe financial statements and footnotes thereto included in the ~~currently~~Corporation’s ~~issued~~filed ~~shares~~Form of10-K ~~Digital~~for the year ended June 30, 2021.

~~The~~7 ~~Share~~Table ~~Exchange Agreement contains customary representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit~~ of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange AgreementContents

The ~~share~~preparation ~~exchange~~of ~~agreement~~financial ~~gave~~statements ~~the~~in ~~other~~conformity ~~party~~with 90U.S. ~~days~~GAAP requires management to ~~transfer~~make ~~shares~~estimates and assumptions that affect application of ~~Digital~~policies toand ~~Bionovate.~~the ~~Bionovate~~reported ~~did~~amounts ~~not~~of ~~receive~~assets ~~these~~and ~~shares~~liabilities ~~yet~~and disclosure of contingent assets and ~~does~~liabilities ~~not~~at ~~own~~the ~~any~~date of ~~Digital~~the ~~Diagnostics~~financial asstatements and the reported amounts of revenues and expenses during the ~~date~~year. Actual results could differ from these estimates. Estimates and their underlying assumptions are reviewed on an ongoing basis. Changes in estimates are recorded in the accounting period in which they are determined. The critical accounting estimates and assumptions in the accompanying unaudited condensed interim financial statements include the provision for unpaid loss and loss adjustment expenses which may result from product warranty provisions; valuation of ~~this~~deferred ~~report~~income taxes; valuation and impairment assessment of intangible assets; goodwill recoverability; and deferred acquisition costs.

~~GOING~~Fair ~~CONCERN~~Value of Financial Instrument

The ~~accompanying~~Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial ~~statements~~instruments ~~have~~and ~~been~~non-financial ~~prepared~~instruments inaccounted ~~conformity~~for ~~with~~at ~~accounting~~fair ~~principles~~value ~~generally~~on ~~accepted~~a inrecurring ~~the~~basis. ~~United~~This ~~States~~new ofaccounting ~~America,~~standard ~~which~~establishes ~~contemplate~~a ~~continuation~~single definition of ~~the~~fair ~~Company~~value asand a ~~going~~framework ~~concern.~~for ~~However~~measuring fair value, sets out a fair value hierarchy to be used to classify the ~~Company~~source ~~has~~of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an ~~accumulated~~instrument ~~deficit~~is carried at ~~March~~fair ~~31,~~value. ~~2021~~The ofCorporation ~~$2,785,213,~~defines isfair invalue aas ~~net~~the ~~liability~~price ~~position~~that ~~and~~would ~~needs~~be ~~cash~~received from selling an asset or paid to ~~maintain~~transfer ~~its~~a ~~operations~~liability in an orderly transaction between market participants at the measurement date.

~~These~~Basic factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and ~~the~~Diluted ~~ability~~Loss toper ~~obtain~~Common ~~additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.~~Stock

8FASB ASC 260 requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive.

~~Table~~For the three months ended September 30, 2021 and 2020, the following common stock equivalents were excluded from the computation of ~~Contents~~diluted net loss per share as the result of the computation was anti-dilutive.

NOTE 2– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	September 30,		September 30,
	2021		2020
	(shares)		(shares)
Convertible notes		26,740,500		26,740,500

~~Basis~~NOTE of3 ~~Presentation~~– ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS

~~The~~As accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of ~~Regulation~~September ~~S-X. Accordingly~~30, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the nine months ended March 31, 2021, ~~are~~and ~~not necessarily indicative of the results that may be expected for the fiscal year ending~~ June 30, 2021~~. For further information~~, ~~refer~~accounts topayable ~~the financial statements~~ and ~~footnotes~~accrued ~~thereto~~liabilities ~~included~~consisted inof ~~the~~as ~~Corporation’s filed Form 10-K for the year ended June 30~~follows, ~~2020.~~

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect application of policies and the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from these estimates. Estimates and their underlying assumptions are reviewed on an ongoing basis. Changes in estimates are recorded in the accounting period in which they are determined. The critical accounting estimates and assumptions in the accompanying unaudited condensed interim financial statements include the provision for unpaid loss and loss adjustment expenses which may result from product warranty provisions; valuation of deferred income taxes; valuation and impairment assessment of intangible assets; goodwill recoverability; and deferred acquisition costs.

	September 30,		June 30,
	2021		2021
Accounts payable	$	38,088	$	31,954
Accrued interest		208,204		192,846
Due to a former related party		41,025		41,025
	$	287,317	$	265,825

~~Fair~~8 ~~Value~~Table of ~~Financial Instrument~~Contents

~~The~~NOTE ~~Corporation~~4 ~~follows~~– ~~FASB~~CONVERTIBLE ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.NOTE

~~When~~Convertible ~~determining~~notes ~~the~~payable ~~fair value measurements for assets and liabilities, which are required to be recorded~~ at ~~fair~~September ~~value~~30, ~~the~~2021 ~~Corporation considers the principal or most advantageous market in which the Corporation would transact~~ and ~~the~~June ~~market-based risk measurements or assumptions that market participants would use in pricing the asset or liability~~30, ~~such as inherent risk~~2021, ~~transfer~~consists ~~restrictions~~of ~~and~~the ~~credit risk.~~following:

The Corporation applies FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments.

	September 30,		June 30,
	2021		2021
Dated November 1, 2016	$	4,439	$	4,439
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375

Less: Unamortized debt discount		-		-
Total convertible notes		185,375		185,375

Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	-	$	-

~~Basic~~For the three months ended September 30, 2021 and ~~Diluted~~2020, ~~Loss~~the ~~per~~Company ~~Common~~recognized ~~Stock~~interest expense of $15,357 and $19,252, respectively. As of September 30, 2021, and June 30, 2021, the Company recorded accrued interest of $208,204 and $192,846, respectively.

~~FASB~~Dated ~~ASC~~November 260 requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable1, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive.2016

9On November 1, 2016, the Company issued a convertible note with a conversion price of $0.005 to extinguish debt of $18,239. The convertible note is unsecured, bears interest at 4% per annum and due and payable on November 1, 2017. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $18,239.

~~Table~~Dated ofJanuary ~~Contents~~1, 2017 - 1

~~For~~On January 1, 2017, the ~~nine~~Company ~~months~~issued ~~ended~~a ~~March~~convertible 31note with a conversion price of $0.005 to extinguish amounts due to related parties of $10,000. ~~2021~~The ~~and~~convertible ~~2020~~note is unsecured, ~~the~~bears ~~following~~interest ~~common~~at ~~stock~~45% ~~equivalents~~per ~~were~~annum, ~~excluded~~has ~~from~~no maturity date and due on demand. The Company recorded a discount on the ~~computation~~convertible note due to a beneficial conversion feature of ~~diluted~~$10,000. ~~net~~During ~~loss~~the ~~per~~year ~~share~~ended asJune 30, 2020, the ~~result~~outstanding balance of the ~~computation~~note was ~~anti-dilutive~~assigned and assumed in an agreement between the original note holder and a 3rd party. The principal amount of $6,200 was converted into 1,240,000 shares of common stock by the new note holder.

	March 31,		March 31,
	2021		2020
	(shares)		(shares)
Convertible notes		26,740,500		24,740,500

Table of Contents

~~NOTE~~Dated 3January –1, ~~ACCOUNTS~~2017 ~~PAYABLE~~– ~~AND ACCRUED LIABILITEIS~~2

AsOn January 1, 2017, the Company issued a convertible note with a conversion price of ~~March~~$0.005 31to extinguish amounts due to related parties of $14,289. ~~2021~~The convertible note is unsecured, bears interest at 45% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $14,289. During the year ended June 30, 2020, ~~accounts~~the ~~payable~~outstanding balance of the note was assigned and ~~accrued~~assumed ~~liabilities~~in ~~consisted~~an agreement between the original note holder and a 3rd party. The principal amount of as$10,489 ~~follows~~and accrued interest of $3,800 was converted into 2,857,800 shares of common stock by the new note holder.

	March 31,		June 30,
	2021		2020
Accounts payable	$	33,878	$	25,702
Accrued expense		—		12,654
Accrued interest		177,651		131,909
Due to a former related party		41,025		41,025
	$	252,554	$	211,290

Dated January 1, 2017 - 3

~~NOTE~~On January 1, 2017, the Company issued a convertible note with a conversion price of $0.005 to extinguish amounts due to related parties of $3,352 (Canadian dollar (“CAD”) $4,500). –The ~~CONVERTIBLE~~convertible ~~NOTE~~note is unsecured, bears interest at 45% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $3,352 (CAD $4,500). The difference of amount was a result of change of exchange rate. During the year ended June 30, 2020, the outstanding balance of the note was assigned and assumed in an agreement between the original note holder and a 3rd party. The principal amount of $3,384 and accrued interest of $1,117 was converted into 900,000 shares of common stock by the new note holder.

~~Convertible~~Dated ~~notes payable at March 31, 2021 and~~ June 30,~~2020,~~ ~~consists of the following:~~2017

	March 31,		June 30,
	2021		2020
Dated November 1, 2016	$	4,439	$	4,439
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375
Less: Unamortized debt discount		—		—
Total convertible notes		185,375		185,375
Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	—	$	—

On June 30, 2017, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $9,969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $9,969.

~~For~~Dated ~~the~~April ~~nine months ended March 31~~1, ~~2021~~2018 ~~and~~- ~~2020,~~1 ~~the Company recognized interest expense of $45,742~~ and $46,824 and amortization of discount, included in interest expense, of $0 and $25,252, respectively. As of March 31, 2021, and June 30, 2020, the Company recorded accrued interest of $177,651 and $131,909, respectively.2

On April 1, 2018, the Company issued 2 convertible notes totaling of $20,000 with a conversion price of $$0.01 to pay a purchase of a patent of $10,000. The convertible note is unsecured, bears interest at 45% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $20,000.

~~Table~~Dated ofJune ~~Contents~~30, 2018

~~Dated~~On ~~November~~June 130, ~~2016~~2018, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $28,376. The convertible note is unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $28,376.

OnDated ~~November~~July 15, ~~2016,~~2018 ~~the~~- ~~Company issued a convertible note with a conversion price of $0.005 to extinguish debt of $18~~1,~~239.~~ ~~The~~2 ~~convertible note is unsecured, bears interest at 4% per annum~~ and ~~due and payable on November 1, 2017. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $18,239.~~3

~~Dated~~On June 30, ~~2017~~2018, the Company issued 3 convertible notes totaling of $60,000 with a conversion price of $0.01 to extinguish amounts due to related parties of $145,523. The convertible notes are unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $60,000.

OnDated ~~June~~December 3031, 2017, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $9,969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $9,969.2018

~~Dated~~On ~~April~~December 131, 2018, –the 1Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,302. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and 2is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,302.

~~On April 1, 2018, the Company issued 2 convertible notes totaling of $20,000 with a conversion price of $0.01 to pay a purchase of a patent of $~~10~~,000.~~ ~~The~~Table convertible note is unsecured, bears interest at 45% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of ~~$20,000.~~Contents

Dated ~~June~~March 3031, ~~2018~~2019

On ~~June~~March 3031, ~~2018~~2019, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $286,~~376~~427. The convertible note is unsecured, bears interest at 3020% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible ~~note~~notes due to a beneficial conversion feature of $286,~~376~~427.

~~Dated~~Effective ~~July~~January 528, ~~2018~~2020, –the 1,Company 2amended a convertible note. The Note reduces the interest rate from 20% to 0 and 3changes the conversion price from $0.01 to $0.0001.

OnEffective ~~June~~January 3028, ~~2018~~2020, the ~~Company~~Note ~~issued 3 convertible notes totaling~~ of $606,~~000~~427 ~~with~~was aassigned ~~conversion~~to ~~price~~Evergreen ofSolutions $0Ltd.01, toand ~~extinguish amounts due to related parties of~~ $~~145~~5,~~523.~~427 ~~The~~was ~~convertible~~immediately ~~notes~~converted ~~are~~for ~~unsecured,~~the ~~bears~~issuance ~~interest~~of ~~at 30% per annum~~54,270,000 ~~has~~shares noof ~~maturity~~common ~~date~~stock ~~and~~of isthe ~~due on demand. The~~ Company ~~recorded~~resulting ain ~~discount on the convertible notes due to~~ a ~~beneficial~~change ~~conversion feature~~ of ~~$60,000~~control.

Dated ~~December~~June 3130, ~~2018~~2019

On ~~December~~June 3130, ~~2018~~2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,~~302~~037. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,~~302~~037.

Dated ~~March~~September 3130, 2019

On ~~March~~September 3130, 2019, the Company issued a convertible note with a conversion price of $0.01005 to pay operating expenses of $~~6,427~~526. The convertible note is unsecured, bears interest at 2035% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $~~6,427~~526.

~~Effective~~Dated ~~January~~December 2831, ~~2020, the Company amended a convertible note. The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.~~2019

~~Effective~~On ~~January~~December 2831, ~~2020~~2019, the ~~Note~~Company issued a convertible note with a conversion price of $~~6,427~~0.005 ~~was~~to ~~assigned~~pay tooperating ~~Evergreen~~expenses ~~Solutions~~of ~~Ltd~~$18,892. The convertible note is unsecured, ~~and~~bears $5interest at 35% per annum,~~427~~ ~~was~~has ~~immediately~~no ~~converted~~maturity ~~for~~date ~~the~~and ~~issuance~~is ofdue ~~54,270,000~~on ~~shares~~demand. ofThe ~~common~~Company ~~stock~~recorded ofa discount on the ~~Company~~convertible ~~resulting~~notes indue to a ~~change~~beneficial conversion feature of ~~control~~$18,892.

11Dated March 31, 2020

~~Table~~On March 31, 2020, the Company issued a convertible note with a conversion price of ~~Contents~~$0.005 to pay operating expenses of $5,834. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $5,834.

Dated June 30, ~~2019~~2020

On June 30, ~~2019~~2020, the Company issued a convertible note with a conversion price of $0.~~005~~001 to pay operating expenses of $172,~~037~~000. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $172,~~037~~000.

~~Dated~~NOTE ~~September~~5 ~~30,~~- ~~2019~~RELATED PARTY TRANSACTIONS

OnDuring the three months ended September 30, ~~2019~~2021, the Company’s ~~issued~~sole aofficer ~~convertible~~paid ~~note with a conversion price of~~ $~~0.005~~144 tofor ~~pay~~ operating expenses on behalf of ~~$526~~the Company. ~~The~~As ~~convertible~~of ~~note~~September ~~is unsecured~~30, ~~bears~~2021 ~~interest~~and atDecember ~~35%~~31, ~~per annum~~2020, ~~has~~the noCompany ~~maturity~~was ~~date~~obligated ~~and~~to isthe ~~due~~officer, onfor ~~demand.~~an ~~The~~unsecured, ~~Company~~non-interest-bearing ~~recorded~~demand aloan ~~discount~~with ~~on the convertible notes due to~~ a ~~beneficial~~balance ~~conversion~~of ~~feature~~$52,153 ofand $~~526~~52,009 respectively.

~~Dated~~11 ~~December~~Table ~~31,~~of ~~2019~~Contents

OnNOTE ~~December~~6 ~~31,~~– 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $18,892. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $18,892.EQUITY

~~Dated~~Preferred ~~March 31, 2020~~Stock

OnThe ~~March 31, 2020, the~~ Company ~~issued~~is aauthorized ~~convertible note with a conversion price of $0.005~~ to ~~pay~~issue ~~operating~~90,000,000 ~~expenses~~shares of ~~$5,834.~~preferred ~~The~~stock ~~convertible note is unsecured, bears interest~~ at ~~35% per annum, has no maturity date and is due on demand. The Company recorded~~ a ~~discount~~par onvalue ~~the convertible notes due to a beneficial conversion feature~~ of $~~5,834~~0.0001.

~~Dated~~No shares were issued and outstanding as of September 30, 2021 and June 30,2021, ~~2020~~respectively.

OnCommon June 30, 2020, the Company issued a convertible note with a conversion price of $0.001 to pay operating expenses of $2,000. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $2,000.Stock

~~NOTE~~The 5Company -is ~~RELATED~~authorized ~~PARTY~~to ~~TRANSACTIONS~~issue 100,000,000 shares of common stock at a par value of $0.0001.

~~During~~As ~~the~~of ~~nine~~September ~~months ended March 31~~30, 2021, ~~the~~and ~~Company’s~~June ~~sole officer paid $45~~30,~~709~~ ~~for operating expenses on behalf of the Company. As of March 31,~~ 2021, ~~the Company was obligated to the officer~~7, ~~for an unsecured~~753,598 ~~non-interest-bearing~~shares ~~demand~~of ~~loan~~common ~~with~~stock awere ~~balance~~issued ofand ~~$45,709~~outstanding.

~~NOTE~~As 6of –September ~~EQUITY~~30, 2021, there were no warrants or options outstanding.

~~Preferred~~NOTE ~~Stock~~7 – SUBSEQUENT EVENT

~~The~~Management ~~Company~~has isevaluated ~~authorized~~subsequent events through the date these financial statements were available to ~~issue~~be ~~90,000,000~~issued. ~~shares~~Based ofon ~~preferred~~our ~~stock~~evaluation atno amaterial ~~par~~events ~~value~~have ofoccurred $0that require disclosure.~~0001.~~

No12 ~~shares~~Table ~~were issued and outstanding as~~ of ~~March 31, 2021 and June 30,2020, respectively.~~Contents

~~Common~~Item ~~Stock~~2. Management’s Discussion and Analysis of Financial Condition or Plan of Operation

~~The~~FORWARD-LOOKING ~~Company is authorized to issue 100,000,000 shares of common stock at a par value of $0.0001.~~STATEMENTS

~~During~~This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the ~~nine~~negative ~~months~~of ~~ended~~these ~~March~~terms 31or other comparable terminology. These statements are only predictions and involve known and unknown risks, ~~2021~~uncertainties and other factors that may cause our or our industry’s actual results, 13levels of activity,~~820~~ performance or achievements to be materially different from any future results,~~000~~ ~~shares~~levels of ~~common~~activity, ~~stock~~performance ~~were~~or ~~canceled~~achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

AsOur ofconsolidated ~~March~~unaudited ~~31,~~financial ~~2021,~~statements are stated in United States Dollars (US$) and ~~June~~are ~~30,~~prepared ~~2020,~~in 45accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans,~~603,598~~ estimates and 59beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include,~~423,598~~ ~~shares~~but ofare ~~common~~not ~~stock~~limited ~~were~~to, ~~issued~~those discussed below and ~~outstanding~~elsewhere in this quarterly report.

AsUnless ofotherwise ~~March~~specified ~~31,~~in ~~2021~~this quarterly report, ~~there~~all ~~were~~dollar noamounts ~~warrants~~are orexpressed ~~options~~in ~~outstanding~~United States dollars and all references to “common stock” refer to shares of our common stock.

12As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Bionovate Technologies Corp., unless otherwise indicated.

~~Table~~Corporate ~~of Contents~~Overview

~~NOTE~~Our 7company ~~– SUBSEQUENT~~was ~~EVENT~~incorporated in the State of Nevada on October 24, 2012. Founded in Calgary, Canada, we were formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, we have set up an office in Guangzhou, China in search of high quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. In November 2016, we expanded our operations to include reselling various energy products and green technology products. We achieved this by acquiring Energy Alliance Labs Inc. (“Energy Alliance”), which is the 80% owner of Human Energy Alliance Laboratories Corp., an Idaho corporation (“HEAL”). HEAL is a “green technology” and retail company with the mission of developing and distributing technologies that relieve its customers of certain burdens, while simultaneously decreasing the energy they use. HEAL’s primary products are mid-sized wind turbines, small solar panels and related controllers and inverters.

~~Management~~On ~~has~~October ~~evaluated~~28, ~~subsequent~~2016, ~~events~~we ~~through~~entered ~~the~~into ~~date~~a ~~these~~share ~~financial~~exchange ~~statements~~agreement ~~were~~with ~~available~~Cohen toMizrahi, bea ~~issued.~~director ~~Based~~of our company, whereby on the same date we issued 4,000,000 shares of our ~~evaluation~~common nostock ~~material~~in ~~events~~exchange ~~have~~for ~~occurred~~100% ~~that~~of ~~require~~the ~~disclosure~~issued and outstanding equity interests of Energy Alliance.

~~Subsequent~~On toNovember ~~March 31~~1, ~~2021~~2016, ~~25,000,000~~Energy ~~shares~~Alliance closed the transactions contemplated under an agreement with certain shareholders of ~~common~~HEAL, ~~stock~~in ~~were~~which ~~returned~~the toshareholders holding 80% of the ~~Company~~outstanding byequity ~~our~~interests ~~major~~of ~~shareholder~~HEAL ~~who~~sold isall ~~also~~of ~~our~~their ~~CEO,~~shares ~~and~~of ~~cancelled~~HEAL to Energy Alliance.

13As a result of such transactions we became the owner of 100% of the issued and outstanding equity interests of Energy Alliance and Energy Alliance became the owner of 80% of the issued and outstanding equity interests of HEAL.

~~Table~~Effective October 4, 2016, we filed a Certificate of ~~Contents~~Dissolution of MJP Holdings Ltd., our wholly-owned subsidiary.

13 ~~Item~~Table ~~2. Management’s Discussion and Analysis~~ of ~~Financial Condition or Plan of Operation~~Contents

~~FORWARD-LOOKING~~Effective ~~STATEMENTS~~November 28, 2016, we entered into a Share Exchange Agreement with MJP Lighting Solutions Ltd., a British Virgin Islands (“BVI”) corporation and Tong Tang and Zhao Hui Ma (the “Shareholders”) whereby the parties exchanged 100% of the issued and outstanding shares of BVI, belonging to our company for the tender of 5,500,000 restricted common shares of our company, belonging to the Shareholders, to our treasury for cancellation.

~~This~~On ~~quarterly~~January ~~report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases~~1, ~~you can identify forward-looking statements by terminology such as “may”~~2017, ~~“should”,~~MJP ~~“expects”,~~entered ~~“plans”,~~into ~~“anticipates”,~~transfer ~~“believes”,~~agreement ~~“estimates”,~~with ~~“predicts”,~~Cohen ~~“potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks~~Mizrahi, ~~uncertainties~~whereby ~~and~~we ~~other~~transferred ~~factors~~100% ~~that may cause our or our industry’s actual results, levels~~ of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the ~~expectations~~issued ~~reflected~~and inoutstanding ~~the~~equity ~~forward-looking~~interests ~~statements are reasonable, we cannot guarantee future results, levels~~ of ~~activity,~~Energy ~~performance~~Alliance orfor ~~achievements.~~consideration ~~Except as required by applicable law, including the securities laws~~ of ~~the United States~~$20,000 wefor dopast ~~not~~services ~~intend~~provided to ~~update~~our ~~any~~company ofby ~~the~~Mr. ~~forward-looking statements to conform these statements to actual results~~Guo.

~~Our~~On ~~consolidated~~December ~~unaudited~~1, ~~financial~~2017, ~~statements~~a ~~are~~majority ~~stated~~of inour ~~United~~stockholders ~~States Dollars (US$)~~ and ~~are~~our ~~prepared~~board inof ~~accordance~~directors ~~with~~approved ~~United~~a ~~States~~change ~~Generally~~of ~~Accepted~~name ~~Accounting~~of ~~Principles. The following discussion should be read in conjunction with~~ our ~~financial~~company ~~statements~~to ~~and~~“Bionovate ~~the~~Technologies ~~related notes that appear elsewhere in this quarterly report~~Corp.” ~~The~~and ~~following~~a ~~discussion~~reverse ~~contains~~stock ~~forward-looking~~split ~~statements~~of ~~that reflect~~ our ~~plans,~~issued ~~estimates~~ and ~~beliefs.~~outstanding ~~Our~~shares ~~actual~~of ~~results~~common ~~could~~stock ~~differ~~on ~~materially~~a ~~from~~fifty ~~those~~(50) ~~discussed~~old infor ~~the~~one ~~forward-looking~~(1) ~~statements.~~new ~~Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report~~basis.

~~Unless~~A ~~otherwise~~Certificate ~~specified~~of inAmendment ~~this~~was ~~quarterly~~filed ~~report,~~with ~~all~~the ~~dollar~~Nevada ~~amounts~~Secretary ~~are~~of ~~expressed~~State inon ~~United~~December ~~States~~11, ~~dollars~~2017 ~~and~~with ~~all~~an ~~references~~effective todate ~~“common stock” refer to shares~~ of ~~our~~December ~~common~~21, ~~stock~~2017.

AsThe ~~used~~name inchange ~~this~~and ~~quarterly~~reverse ~~report,~~split ~~the~~became ~~terms~~effective ~~“we”,~~with ~~“us”,~~the ~~“our”~~OTC ~~and~~Markets ~~“our~~at ~~company”~~the ~~mean~~opening ~~Bionovate~~of ~~Technologies~~trading ~~Corp.~~on December 21, ~~unless~~2017 ~~otherwise~~under ~~indicated~~the symbol “BIIO”.

~~Corporate~~Effective ~~Overview~~January 11, 2018, we entered into a Patent Purchase and License Agreement with Lily Innovation Advisors Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 7,963,959 “Automated Cryogenic Skin Treatment” (the “Lily Patent”). We paid $10,000 as consideration for the Lily Patent, and agreed to pay royalties of one percent (1%) of the (a) net sales of all products that are derived from the invention covered under the Lily Patent and sold by our company or any licensees or transferees and (b) licensing fees, royalties or similar payments in respect of the Lily Patent received by any such entity, such royalties to be paid quarterly in January, April, July and October for all sales incurred in the previous calendar quarter.

~~Our~~The ~~company~~assignment ~~was incorporated in the State~~ of ~~Nevada on October 24, 2012. Founded in Calgary, Canada, we were formed and organized to capitalize on new opportunities found in~~ the ~~North~~Lily ~~American~~Patent ~~market~~was ~~for~~registered ~~light-emitting~~with ~~diode (“LED”) lighting. With China as~~ the ~~manufacturing backbone of future LED products, we have set up an office in Guangzhou, China in search of high quality products offered by reputable manufacturers to be introduced to Canada, the~~ United States, ~~and~~Patent ~~abroad. In November 2016, we expanded our operations to include reselling various energy products~~ and ~~green~~Trademark ~~technology~~Office ~~products.~~on WeJanuary ~~achieved this by acquiring Energy Alliance Labs Inc. (“Energy Alliance”)~~31, ~~which is the 80% owner of Human Energy Alliance Laboratories Corp~~2018., an Idaho corporation (“HEAL”). HEAL is a “green technology” and retail company with the mission of developing and distributing technologies that relieve its customers of certain burdens, while simultaneously decreasing the energy they use. HEAL’s primary products are mid-sized wind turbines, small solar panels and related controllers and inverters.

OnThe ~~October~~foregoing ~~28,~~description ~~2016,~~of wethe ~~entered~~Patent ~~into~~Purchase aand ~~share~~License ~~exchange~~Agreement ~~agreement~~is ~~with~~included ~~Cohen~~to ~~Mizrahi,~~provide ainformation ~~director~~regarding ofits ~~our~~terms. ~~company,~~It ~~whereby~~does onnot ~~the~~purport ~~same~~to ~~date~~be wea ~~issued~~complete ~~4,000,000~~description ~~shares~~and ofis ~~our~~qualified ~~common~~by ~~stock~~its inentirety ~~exchange~~by ~~for~~reference ~~100%~~to the full text of the ~~issued~~Patent Purchase and ~~outstanding~~License ~~equity~~Agreement, ~~interests~~which ofis ~~Energy~~filed ~~Alliance~~as Exhibit 10.1 hereto and is incorporated herein by reference.

OnEffective ~~November~~February 119, ~~2016~~2018, ~~Energy~~we ~~Alliance~~entered ~~closed~~into ~~the~~a ~~transactions~~Patent ~~contemplated~~Purchase ~~under~~and anLicense ~~agreement~~Agreement with ~~certain~~Ramot ~~shareholders~~at Tel-Aviv University Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 6,858,007 “Method and system for automatic classification and quantitative evaluation of ~~HEAL~~adnexal masses based on a cross-sectional or projectional images of the adnexs” (the “Ramot Patent”). We paid $10,000 inas ~~which~~consideration for the ~~shareholders~~Ramot ~~holding~~Patent 80and agreed to pay royalties of one percent (1%) of the ~~outstanding~~net ~~equity~~sales ~~interests~~ of ~~HEAL~~all products sold ~~all~~by ofour ~~their~~company ~~shares~~that ofare ~~HEAL~~derived from the invention covered by the Ramot Patent, such royalties to ~~Energy~~be ~~Alliance~~paid quarterly in January, April, July and October from sales incurred in the previous calendar quarter.

13The assignment of the Ramot Patent was registered with the United States Patent and Trademark Office on March 5, 2018.

~~Table~~On October 1, 2019, a majority of ~~Contents~~our shareholders approved a reverse stock split on a basis of 100 old shares for one (1) new share of our issued and outstanding common stock. No fractional shares of common stock will be issued as a result of the reverse split. Any fractional shares that would have resulted from the reverse split will be rounded up to the next whole number.

As a result of ~~such transactions we became~~ the ~~owner~~reverse ofsplit, ~~100%~~our ~~of the~~ issued and outstanding ~~equity~~shares ~~interests~~ of ~~Energy~~common ~~Alliance~~stock ~~and~~will ~~Energy~~decrease ~~Alliance~~from ~~became~~15,579,749 ~~the~~to ~~owner~~155,798 shares of ~~80%~~common ofstock. ~~the~~We ~~issued~~confirm ~~and~~that ~~outstanding~~our ~~equity~~authorized ~~interests~~capital ofwill ~~HEAL~~remain unchanged.

~~Effective~~14 ~~October~~Table ~~4, 2016, we filed a Certificate~~ of ~~Dissolution of MJP Holdings Ltd., our wholly-owned subsidiary.~~Contents

~~Effective~~The ~~November~~reverse ~~28,~~split ~~2016,~~has webeen ~~entered~~reviewed ~~into~~by athe ~~Share~~Financial ~~Exchange~~Industry ~~Agreement~~Regulatory ~~with~~Authority ~~MJP Lighting Solutions Ltd., a British Virgin Islands~~ (~~“BVI”~~FINRA) ~~corporation~~ and ~~Tong~~has ~~Tang~~been ~~and~~approved ~~Zhao~~for ~~Hui~~filing Mawith ~~(the~~an ~~“Shareholders”)~~effective ~~whereby~~date ~~the parties exchanged 100%~~ of ~~the~~January ~~issued and outstanding shares of BVI~~9, ~~belonging~~2020. toAll ~~our~~share ~~company~~and ~~for~~per ~~the~~share ~~tender~~information ofin ~~5,500,000~~these ~~restricted~~financial ~~common~~statements ~~shares~~retroactively ofreflect ~~our~~this ~~company,~~stock ~~belonging to the Shareholders, to our treasury for cancellation~~distribution.

OnEffective January 128, ~~2017~~2020, ~~MJP~~the ~~entered~~Company ~~into~~amended ~~transfer~~a ~~agreement~~20% ~~with~~Convertible ~~Cohen~~Note ~~Mizrahi,~~originally ~~whereby~~issued weon ~~transferred~~March ~~100%~~31, of2019 (the ~~issued~~“Note”). ~~and~~The ~~outstanding~~Note ~~equity~~reduces ~~interests~~the ofinterest ~~Energy~~rate ~~Alliance~~from ~~for consideration of $~~20~~,000~~% ~~for~~to ~~past~~0 ~~services~~and ~~provided~~changes tothe ~~our~~conversion ~~company~~price byfrom Mr$0.01 ~~Guo~~to $0.0001.

OnEffective ~~December~~January 128, ~~2017~~2020, athe ~~majority~~Note ofwas ~~our~~assigned ~~stockholders and our board of directors approved a change of name of our company~~ to ~~“Bionovate~~Evergreen ~~Technologies~~Solutions ~~Corp~~Ltd.”, and awas ~~reverse~~immediately ~~stock~~converted ~~split~~for ofthe ~~our~~issuance ~~issued~~of ~~and~~54,270,000 ~~outstanding~~ shares of common stock onof athe ~~fifty~~Company ~~(50)~~resulting ~~old~~in ~~for~~a ~~one~~change ~~(1)~~of ~~new basis~~control.

AOn ~~Certificate~~February 3, 2020, Cohen Mizrahi resigned as a director and as an officer of ~~Amendment~~our ~~was~~company. ~~filed~~Dr. ~~with~~Mizrahi’s resignation was not the ~~Nevada~~result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations, policies or practices. On February 3, 2020, David Magana Gonzalez was appointed as a director to replace Dr. Mizrahi and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of ~~State~~our company.On July 22, 2020, David Magna Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the result of a disagreement between Mr. Gonzalez and our company on ~~December~~any 11matter relating to our company’s operations, ~~2017~~policies ~~with~~or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.On September 28, 2020, Marc Applbaum resigned as a director and as an ~~effective~~officer ~~date~~of our company. Mr. Applbaums resignation was not the result of ~~December~~a 21disagreement between Mr. Applbaum and our company on any matter relating to our company’s operations, ~~2017~~policies or practices. On September 28, 2020, Aleksander Vucak was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

~~The~~On ~~name~~October ~~change~~7, ~~and~~2020, ~~reverse~~Bionovate ~~split~~Technologies ~~became~~Corp. ~~effective~~(the ~~with~~“Company”) ~~the~~entered ~~OTC~~into ~~Markets~~a atShare Exchange Agreement (the ~~opening~~“Share ofExchange ~~trading~~Agreement”) onfacilitated ~~December~~between 21Evergreen Solutions, ~~2017~~Ltd, ~~under~~a ~~the~~private ~~symbol~~Company (“~~BIIO~~Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).

~~Effective~~Pursuant ~~January~~to ~~11,~~the ~~2018,~~Share weExchange ~~entered~~Agreement, ~~into~~in aexchange ~~Patent~~for ~~Purchase~~the ~~and~~acquisition ~~License~~of ~~Agreement~~all ~~with~~of ~~Lily~~the ~~Innovation~~outstanding ~~Advisors~~Company ~~Ltd.~~shares ~~wherein~~which weEvergreen ~~agreed~~owns, to ~~purchase~~wit, ~~the rights to U.S. Patent No. 7~~54,~~963~~270,~~959~~000 ~~“Automated~~shares ~~Cryogenic Skin Treatment”~~ (the “~~Lily~~Exchange ~~Patent~~Shares”)~~. We paid $10~~,~~000~~ asthe ~~consideration~~Company ~~for~~will ~~the~~receive ~~Lily Patent~~12,500 ~~and~~shares ~~agreed to pay royalties~~ of ~~one~~Digital ~~percent~~Diagnostics ~~(1%)~~AG ~~of the~~ (a“Digital”) ~~net~~owned ~~sales of all products that are derived from the invention covered under the Lily Patent and sold~~ by ~~our~~Human ~~company or any licensees or transferees and (b) licensing fees~~Data, ~~royalties~~which orequates ~~similar~~to ~~payments~~25% ~~in respect~~ of the ~~Lily~~currently ~~Patent~~issued ~~received~~shares byof ~~any such entity, such royalties to be paid quarterly in January, April, July and October for all sales incurred in the previous calendar quarter~~Digital.

The ~~assignment~~Share ofExchange ~~the~~Agreement ~~Lily~~contains ~~Patent~~customary ~~was~~representations ~~registered~~and ~~with~~warranties made by the ~~United~~Company, ~~States~~on ~~Patent~~the one hand, and ~~Trademark~~Evergreen ~~Office~~and Human Data on ~~January~~the 31other hand, ~~2018~~made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement.

~~The~~During ~~foregoing description of~~ the ~~Patent~~year ~~Purchase~~ended ~~and~~June ~~License~~30, ~~Agreement~~2021, is51,670,000 ~~included~~shares ~~to provide information regarding its terms. It does not purport to be a complete description and is qualified by its entirety by reference to the full text~~ of ~~the~~common ~~Patent~~stock ~~Purchase~~were ~~and License Agreement~~canceled, which isowned ~~filed~~by asour ~~Exhibit~~major ~~10.1~~shareholder ~~hereto~~who ~~and~~ is ~~incorporated~~also ~~herein~~our ~~by reference.~~CEO

~~Effective~~Our ~~February~~corporate ~~19,~~address ~~2018,~~is weGewerbestrasse ~~entered~~10, ~~into a Patent Purchase and License Agreement with Ramot at Tel-Aviv University Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 6~~Cham,~~858,007~~ ~~“Method~~Switzerland ~~and system for automatic classification and quantitative evaluation of adnexal masses based on a cross-sectional or projectional images of the adnexs” (the “Ramot Patent”)~~6330. We ~~paid~~do ~~$10,000~~not ashave ~~consideration~~a ~~for~~corporate the Ramot Patent and agreed to pay royalties of one percent (1%) of the net sales of all products sold by our company that are derived from the invention covered by the Ramot Patent, such royalties to be paid quarterly in January, April, July and October from sales incurred in the previous calendar quarterwebsite.

~~The~~We ~~assignment~~do ofnot ~~the~~have ~~Ramot~~any ~~Patent was registered with the United States Patent and Trademark Office on March 5, 2018~~subsidiaries.

~~October~~We 1,have ~~2019,~~not abeen ~~majority~~subject of our shareholders approved a reverse stock split on a basis of 100 old shares for one (1) new share of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding shares of common stock decreased from 15,579,749 to ~~155,798~~any ~~shares of common stock~~bankruptcy, ~~our~~receivership ~~authorized~~or ~~capital~~similar ~~remained unchanged~~proceeding. ~~The reverse split became effective with the OTC Markets at the opening of trading on January 9, 2020.~~

14Current Business

~~Table~~We are a medical device company that intends to develop the first automated treatment for age spots (solar lentigines). The technology (patent issued) uses a “scan and treat” protocol that removes age spots accurately and completely without disturbing the surrounding skin area. Current methods of ~~Contents~~treatment (lasers and manual liquid nitrogen spray devices) are either painful, costly, or require a physician to perform the procedure. The Bionovate system would be safe and would produce excellent results and can be used for other types of skin lesions. Its operation would require minimal user interaction and users can be trained in minutes. We are also looking into developing novel cancer detection methods based on its electronic imaging patent.

~~Effective~~15 ~~January~~Table ~~28,~~of 2020, the Company amended a 20% Convertible Note originally issued on March 31, 2019 (the “Note”). The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.Contents

~~Effective~~Results ~~January 28, 2020, the Note was assigned to Evergreen Solutions Ltd., and was immediately converted for the issuance~~ of ~~54,270,000 shares of common stock of the Company resulting in a change of control.~~Operations

OnOur February 3, 2020, Cohen Mizrahi resigned as a director and as an officer of our company. Dr. Mizrahi’s resignation was not the result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations, ~~policies~~for or practices. On February 3, 2020, David Magana Gonzalez was appointed as a director to replace Dr. Mizrahi and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On July 22, 2020, David Magna Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the ~~result~~three ofmonths aended disagreement between Mr. Gonzalez and our company on any matter relating to our company’s operations, policies or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On September 2830, ~~2020,~~2021 ~~Marc Applbaum resigned as a director~~ and as an officer of our company. Mr. Applbaums resignation was not the result of a disagreement between Mr. Applbaum and our company on any matter relating to our company’s operations, policies or practices. On September 28, 2020, ~~Aleksander~~are ~~Vucak~~outlined ~~was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.~~below:

OnThree ~~October~~months 7,ended ~~2020,~~September ~~Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions~~30, ~~Ltd,~~2021 acompared ~~private~~to ~~Company~~three ~~(“Evergreen”),~~months ~~and~~ended ~~Human~~September ~~Data AG~~30, ~~a private Switzerland Company (“Human Data”)~~2020.

Pursuant to the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit, 54,270,000 shares (the “Exchange Shares”), the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.

	Three Months Ended
	September 30,				Change
	2021		2020		Amount			%
Revenues	$	-	$	-	$	-			-
Operating Expenses		6,279		3,622		2,657			73	%
Total other expense		15,357		19,252		(3,895	)	(20		%)
Net Loss	$	21,636	$	22,874	$	(1,238	)	(5		%)

~~The~~For ~~Share~~the ~~Exchange~~three ~~Agreement~~months ~~contains~~ended ~~customary~~September ~~representations~~30, 2021 and ~~warranties~~2020, ~~made~~we byhad ~~the~~no ~~Company,~~revenue. onExpenses for the ~~one~~three ~~hand~~months ended September 30, ~~and~~2021 ~~Evergreen~~totaled ~~and~~$21,636 ~~Human~~resulting ~~Data~~in ona ~~the~~net ~~other~~loss ~~hand~~of $21,636 ~~made~~as ~~solely~~compared ~~for~~to ~~the~~a ~~benefit~~net loss of ~~the other~~$22,874 ~~which~~for inthe ~~certain~~three ~~cases~~months ~~are~~ended ~~subject~~September to30, ~~specified~~2020. ~~exceptions~~The ~~and~~decrease ~~qualifications~~in ~~contained~~net inloss for the ~~Share~~three ~~Exchange~~months ~~Agreement~~ended orSeptember in30, ~~information~~2021 ~~provided~~is ~~pursuant~~a toresult ~~certain~~of ~~disclosure~~a ~~schedules~~decrease toin ~~the~~interest ~~Share~~expenses ~~Exchange~~offset ~~Agreement~~by an increase in professional fees.

~~The~~Liquidity ~~share exchange agreement gave the other party 90 days to transfer shares of Digital to Bionovate. Bionovate did not receive these shares yet~~ and ~~does~~Capital ~~not own any of Digital Diagnostics as of the date of this report.~~Resources

OnThe ~~December~~following 4,table ~~2020,~~provides 13selected financial data about our company as of September 30,~~820,000~~ ~~shares~~2021 ~~were~~and ~~canceled~~June by30, ~~the~~2021, ~~CEO~~respectively.

~~Our~~Working ~~corporate~~Capital ~~address is Gewerbestrasse 10, Cham, Switzerland 6330. We do not have a corporate website.~~

We do not have any subsidiaries.

	September 30,			June 30,			Change
	2021			2021			Amount			%
Current Assets	$	-		$	-		$	-			-
Current Liabilities	$	524,845		$	503,209			21,636			4	%
Working Capital (Deficit)	$	(524,845	)	$	(503,209	)	$	(21,636	)		4	%

WeCash ~~have not been subject to any bankruptcy, receivership, or similar proceeding.~~Flows

Current Business

	Three Months Ended
	September 30,
	2021		2020
Net Cash Provided by Operating Activities	$	-	$	-
Net Cash Provided by Investing Activities	$	-	$	-
Net Cash Provided by Financing Activities	$	-	$	-
Net Change in Cash During the Period	$	-	$	-

~~Bionovate~~On ~~Technologies~~September ~~Corp.~~30, ~~focuses~~2021, onour ~~investments~~Company’s ~~and~~cash ~~the~~balance ~~marketing~~was of$0 ~~patents~~ and ~~licenses~~total ~~which~~assets ~~bring~~were ~~healthcare and lifestyle diagnostics to your smartphone~~$0. ~~With~~On ~~strong~~June ~~emphasis~~30, ~~on digital transformation~~2021, ~~the~~our ~~company~~Company’s ~~intends~~cash tobalance ~~build~~was an$0 ~~FDA-approved ecosystem of medical devices, biosensors~~ and ~~mobile~~total ~~applications~~assets ~~to turn tests that~~ were ~~previously only done in physical labs into tests that can be carried through by anyone with a mobile device~~$0.

15On September 30, 2021, our Company had total liabilities of $524,845, compared with total liabilities of $503,209 as at June 30, 2021.

16 Table of Contents

~~Results~~On September 30, 2021, our Company had working capital deficiency of ~~Operations~~$524,845 compared with working capital deficiency of $503,209 as at June 30, 2021. The increase in working capital was primarily attributed to an increase in accounts payable and accrued liabilities and due to related party.

~~Our~~Cash ~~operations~~Flow ~~for~~from ~~the~~Operating ~~three and nine ended March 31, 2021 and 2020 are outlined below:~~Activities

~~Three~~During the three months ended ~~March~~September 3130, 2021, our Company provided $0 by operating activities, compared to $0 provided by operating activities during the three months ended ~~March~~September 3130, 2020.

		Three Months Ended
		March 31,				Change
		2021		2020		Amount		%
Revenues	$	—	$	—	$	—		—
Operating Expenses		16,685		2,748		13,937		507	%
Total other expense		14,980		21,390		(6,410	)	(30)	%
Net Loss	$	31,665	$	24,138	$	7,527		31	%

Cash Flow from Investing Activities

~~For~~During the three months ended ~~March~~September 3130, 2021 and 2020, weour ~~had~~Company nodid ~~revenue.~~not ~~Expenses~~have ~~for~~any ~~the~~investing ~~three months ended March 31, 2021 totaled $31,665 resulting in a net loss of $31,665 as compared to a net loss of $24,138 for the three months ended March 31, 2020~~activities. ~~The increase in net loss for the three months ended March 31, 2021 is a result of an increase in professional fees offset by a decrease in interest expenses.~~

~~Nine~~Cash ~~months~~Flow ~~ended~~from ~~March~~Financing ~~31, 2021 compared to nine months ended March 31, 2020.~~Activities

		Nine Months Ended
		March 31,				Change
		2021		2020		Amount		%
Revenues	$	—	$	—	$	—		—
Operating Expenses		40,995		27,110		13,885		51	%
Total other expense		45,978		71,973		(25,995	)	(36)	%
Net Loss	$	86,973	$	99,083	$	(12,110	)	(12)	%

During the three months ended September 30, 2021 and 2020, our Company did not have any investing activities.

~~For~~Off-Balance ~~the~~Sheet nine months ended March 31, 2021 and 2020, we had no revenue. Expenses for the nine months ended March 31, 2021 totaled $86,973 resulting in a net loss of $86,973 as compared to a net loss of $99,083 for the nine months ended March 31, 2020. The decrease in net loss for the nine months ended March 31, 2021 is a result of a decrease in interest expense offset by an increase in professional fees.Arrangements

~~Liquidity~~We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and ~~Capital~~capital ~~Resources~~expenditures or capital resources that are material to stockholders.

~~The~~Critical ~~following~~Accounting ~~table provides selected financial data about our company as of March 31, 2021 and June 30, 2020, respectively.~~Policies

~~Working~~Revenue ~~Capital~~ Recognition

		March 31,			June 30,			Change
		2021			2020			Amount		%
Current Assets	$	—		$	—		$	—		—
Current Liabilities	$	483,638		$	396,665			86,973		22	%
Working Capital (Deficit)	$	(483,638	)	$	(396,665	)	$	(86,973	)	22	%

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

16· identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied.

~~Table~~Recent ofAccounting ~~Contents~~Pronouncements

~~Cash~~We ~~Flows~~have implemented all new accounting pronouncements that are in effect and that may impact our financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations. Our company regularly reviews and analyses the recent accounting pronouncements.

		Nine Months Ended
		March 31,
		2021		2020
Net Cash Provided by Operating Activities	$	—	$	—
Net Cash Provided by Investing Activities	$	—	$	—
Net Cash Provided by Financing Activities	$	—	$	—
Net Change in Cash During the Period	$	—	$	—

Table of Contents

OnItem ~~March 31, 2021, our Company’s cash balance was $0 and total assets were $0~~3. OnQuantitative ~~June 30, 2020, our Company’s cash balance was $0~~ and ~~total~~Qualitative ~~assets~~Disclosures ~~were~~About ~~$0.~~Market Risk

OnAs ~~March~~a ~~31,~~“smaller ~~2021,~~reporting ~~our Company had total liabilities of $483~~company”,~~638,~~ ~~compared~~we ~~with~~are ~~total~~not ~~liabilities~~required ofto ~~$396,665~~provide asthe atinformation ~~June~~required ~~30,~~by ~~2020~~this Item.

OnItem ~~March 31, 2021, our Company had working capital deficiency of $483,638 compared with working capital deficiency of $396,665 as at June 30, 2020~~4. ~~The~~Controls ~~increase in working capital was primarily attributed to an increase in accounts payable~~ and ~~accrued liabilities and due to related party.~~Procedures

~~Cash~~Evaluation ~~Flow~~of ~~from~~Disclosure ~~Operating~~Controls ~~Activities~~and Procedures

~~During~~Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the ~~nine~~Exchange ~~months~~Act) ~~ended~~that ~~March~~is 31designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, ~~2021~~processed, ~~our~~summarized ~~Company~~and ~~provided~~reported, $0within bythe ~~operating~~time ~~activities~~periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, ~~compared~~without limitation, controls and procedures designed to $0ensure ~~provided~~that information required to be disclosed by ~~operating~~an ~~activities~~issuer ~~during~~in the ~~nine~~reports ~~months~~that ~~ended~~it ~~March~~files 31or submits under the Exchange Act is accumulated and communicated to the issuer’s management, ~~2020~~including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~Cash~~An ~~Flow~~evaluation ~~from~~was ~~Investing~~conducted ~~Activities~~under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2021. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the period ended September 30, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

~~During~~Changes ~~the~~in ~~nine~~Internal ~~months~~Control ~~ended~~Over ~~March~~Financial ~~31, 2021 and 2020, our Company did not have any investing activities.~~Reporting

~~Cash~~There ~~Flow~~have ~~from~~been ~~Financing~~no ~~Activities~~changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~During~~18 ~~the~~Table ~~nine~~of ~~months ended March 31, 2021 and 2020, our Company did not have any investing activities.~~Contents

~~Off~~PART II -~~Balance~~ ~~Sheet~~OTHER ~~Arrangements~~INFORMATION

WeItem ~~have~~1. noLegal off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.Proceedings

~~Critical~~We ~~Accounting~~know ~~Policies~~of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

~~Revenue~~Item ~~Recognition~~1A. Risk Factors

~~Revenues~~As ~~are~~a ~~recognized~~“smaller ~~when~~reporting ~~control~~company”, ofwe ~~the promised goods or services~~ are ~~transferred~~not torequired ~~a customer, in an amount that reflects the consideration that the Company expects~~ to ~~receive~~provide ~~in exchange for those goods or services. The Company applies~~ the ~~following~~information ~~five~~required ~~steps~~by inthis ~~order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:~~Item.

·Item ~~identify~~2. ~~the~~Unregistered ~~contract~~Sales ~~with~~of aEquity ~~customer;~~Securities ~~· identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract;~~ and ·Use ~~recognize~~of ~~revenue as the performance obligation is satisfied.~~Proceeds

17None.

~~Table~~Item of3. ~~Contents~~Defaults Upon Senior Securities

~~Recent Accounting Pronouncements~~None.

WeItem have implemented all new accounting pronouncements that are in effect and that may impact our financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations4. ~~Our~~Mine ~~company~~Safety ~~regularly reviews and analyses the recent accounting pronouncements.~~Disclosures

~~Item~~Not 3Applicable. ~~Quantitative and Qualitative Disclosures About Market Risk~~

AsItem a5. ~~“smaller~~Other ~~reporting company”, we are not required to provide the information required by this Item.~~Information

~~Item 4. Controls and Procedures~~None

~~Evaluation~~19 Table of ~~Disclosure Controls and Procedures~~Contents

~~Our~~Item management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms6. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.Exhibits

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the period ended March 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002
(32)		Section 1350 Certifications
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002
101*		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

~~Changes~~* inFiled ~~Internal Control Over Financial Reporting~~herewith.

~~There~~** ~~have~~XBRL ~~been~~Information nois ~~changes~~furnished inand ~~our~~not ~~internal~~filed ~~control~~or ~~over~~a ~~financial~~part ~~reporting~~of ~~that~~a ~~occurred~~registration ~~during~~statement or prospectus for purposes of Sections 11 or 12 of the ~~quarter~~Securities ~~ended~~Act ~~March~~of 311933, ~~2021~~as amended, ~~that~~is ~~have~~deemed ~~materially~~not ~~affected,~~filed orfor ~~are~~purposes ~~reasonably~~of ~~likely~~Section to18 ~~materially~~of ~~affect~~the Securities Exchange Act of 1934, ~~our~~as ~~internal~~amended, ~~control~~and ~~over~~otherwise ~~financial~~is ~~reporting~~not subject to liability under these sections.

1820 Table of Contents

~~Table of Contents~~SIGNATURES

In ~~PART~~accordance IIwith -Section ~~OTHER~~13 ~~INFORMATION~~or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Item 1. Legal Proceedings

		BIONOVATE TECHNOLOGIES CORP.
		(Registrant)

Dated: November 15, 2021		/s/ Aleksander Vucak
		Aleksander Vucak
		President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.21

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None

Table of Contents

Item 6. Exhibits

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002
(32)		Section 1350 Certifications
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002
101*		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** XBRL Information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BIONOVATE TECHNOLOGIES CORP.
		(Registrant)
Dated: May 17, 2021		/s/ Aleksander Vucak
		Aleksander Vucak
		President, Chief Executive Officer, Chief FinancialOfficer, Secretary, Treasurer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · Bionovate Technologies Corp.